A detailed history of Harfst & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Harfst & Associates, Inc. holds 2,641 shares of ABBV stock, worth $463,706. This represents 0.12% of its overall portfolio holdings.

Number of Shares
2,641
Previous 2,681 1.49%
Holding current value
$463,706
Previous $459,000 13.51%
% of portfolio
0.12%
Previous 0.11%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$163.84 - $199.33 $6,553 - $7,973
-40 Reduced 1.49%
2,641 $521,000
Q1 2024

Aug 01, 2024

BUY
$159.82 - $182.1 $428,477 - $488,210
2,681 New
2,681 $488,000
Q3 2023

Nov 07, 2023

SELL
$133.59 - $154.65 $31,393 - $36,342
-235 Reduced 8.06%
2,681 $399,000
Q2 2023

Aug 07, 2023

BUY
$132.51 - $164.9 $31,139 - $38,751
235 Added 8.77%
2,916 $392,000
Q1 2022

Apr 28, 2022

SELL
$131.98 - $163.75 $7,258 - $9,006
-55 Reduced 2.01%
2,681 $434,000
Q4 2021

Feb 07, 2022

BUY
$107.43 - $135.93 $5,908 - $7,476
55 Added 2.05%
2,736 $370,000
Q3 2020

Nov 04, 2020

BUY
$85.91 - $100.83 $1,374 - $1,613
16 Added 0.6%
2,681 $234,000
Q3 2019

Nov 14, 2019

BUY
$62.98 - $75.72 $167,841 - $201,793
2,665 New
2,665 $201,000
Q2 2019

Aug 14, 2019

SELL
$65.7 - $83.98 $177,061 - $226,326
-2,695 Closed
0 $0
Q1 2018

May 07, 2018

BUY
$92.01 - $123.21 $43,704 - $58,524
475 Added 21.4%
2,695 $255,000
Q4 2017

Feb 09, 2018

BUY
$89.56 - $98.21 $198,823 - $218,026
2,220 New
2,220 $214,000
Q3 2017

Nov 07, 2017

SELL
$69.85 - $89.22 $155,067 - $198,068
-2,220 Closed
0 $0
Q2 2017

Aug 11, 2017

BUY
N/A
2,220
2,220 $160,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Harfst & Associates, Inc. Portfolio

Follow Harfst & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harfst & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harfst & Associates, Inc. with notifications on news.